Citations for
1CCDC80, JAK2
Identification of Steroid-Sensitive Gene-1/Ccdc80 as a JAK2-Binding Protein.
O'Leary EE, Mazurkiewicz-Muñoz AM, Argetsinger LS, Maures TJ, Huynh HT, Carter-Su C.
Mol Endocrinol 27(4):619-34. doi: 10.1210/me.2011-1275. Epub 2013 Feb 28. 2013
2JAK2, SLC6A12
Up-regulation of the betaine/GABA transporter BGT1 by JAK2.
Hosseinzadeh Z, Shojaiefard M, Bhavsar SK, Lang F.
Biochem Biophys Res Commun 420(1):172-7. doi: 10.1016/j.bbrc.2012.02.137. Epub 2012 Mar 3. 2012
3JAK2, SLC5A3
Down-regulation of the myoinositol transporter SMIT by JAK2.
Hosseinzadeh Z, Bhavsar SK, Lang F.
Cell Physiol Biochem 30(6):1473-80. doi: 10.1159/000343335. Epub 2012 Nov 30. 2012
4JAK2, LCK, LMO2
Nuclear localization of lymphocyte-specific protein tyrosine kinase (Lck) and its role in regulating LIM domain only 2 (Lmo2) gene.
Venkitachalam S, Chueh FY, Yu CL.
Biochem Biophys Res Commun 417(3):1058-62. doi: 10.1016/j.bbrc.2011.12.095. Epub 2011 Dec 27. 2012
5JAK2
The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis.
Smalberg JH, Koehler E, Darwish Murad S, Plessier A, Seijo S, Trebicka J, Primignani M, de Maat MP, Garcia-Pagan JC, Valla DC, Janssen HL, Leebeek FW; European Network for Vascular Disorders of the Liver (EN-Vie).
Blood 117(15):3968-73. Epub 2011 Mar 1. 2011
6BCR, JAK2
Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.
Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, Bhatia R, Priebe W, Arlinghaus R.
Leukemia 25(3):463-72. Epub 2010 Dec 24. 2011
7JAK2
Jak2 is necessary for neuroendocrine control of female reproduction.
Wu S, Divall S, Hoffman GE, Le WW, Wagner KU, Wolfe A.
J Neurosci. 31(1):184-92. 2011
8JAK2, PRV
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian JJ, McMullin MF, Ruggeri M, Besses C, Vannucchi AM, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortmann CA, Pietra D, Pascutto C, Haferlach T, Cazzola M.
Blood 117(10):2813-6. Epub 2011 Jan 11. 2011
9JAK2
JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma.
Van Roosbroeck K, Cox L, Tousseyn T, Lahortiga I, Gielen O, Cauwelier B, De Paepe P, Verhoef G, Marynen P, Vandenberghe P, De Wolf-Peeters C, Cools J, Wlodarska I.
Blood 117(15):4056-64. Epub 2011 Feb 15. 2011
10JAK2, SLC5A1
Stimulation of the glucose carrier SGLT1 by JAK2.
Hosseinzadeh Z, Bhavsar SK, Shojaiefard M, Saxena A, Merches K, Sopjani M, Alesutan I, Lang F.
Biochem Biophys Res Commun 408(2):208-13. Epub 2011 Mar 21. 2011
11CDKN1B, JAK2
Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control.
Jäkel H, Weinl C, Hengst L.
Oncogene 30(32):3502-12. doi: 10.1038/onc.2011.68. Epub 2011 Mar 21. 2011
12ECYT2, JAK2, VHL
Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.
Russell RC, Sufan RI, Zhou B, Heir P, Bunda S, Sybingco SS, Greer SN, Roche O, Heathcote SA, Chow VW, Boba LM, Richmond TD, Hickey MM, Barber DL, Cheresh DA, Simon MC, Irwin MS, Kim WY, Ohh M.
Nat Med 17(7):845-53. doi: 10.1038/nm.2370. 2011
13ACE2, JAK2, SLC6A19, TMEM27
Stimulation of the amino acid transporter SLC6A19 by JAK2.
Bhavsar SK, Hosseinzadeh Z, Merches K, Gu S, Bröer S, Lang F.
Biochem Biophys Res Commun 414(3):456-61. Epub 2011 Sep 19. 2011
14JAK2
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.
Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, Jensen ON, Xu CF, Neubert TA, Skoda RC, Hubbard SR, Silvennoinen O.
Nat Struct Mol Biol 18(9):971-6. doi: 10.1038/nsmb.2099. 2011
15CRLF2, JAK2
CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis.
Roll JD, Reuther GW.
Cancer Res 70(19):7347-52. Epub 2010 Aug 31. Review.PMID: 20807819 2010
16JAK2
Stat1 mediates an auto-regulation of hsp90beta gene in heat shock response.
Cheng MB, Zhang Y, Zhong X, Sutter B, Cao CY, Chen XS, Cheng XK, Zhang Y, Xiao L, Shen YF.
Cell Signal. 22(8):1206-13. 2010
17JAK2
A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.
Iwanaga E, Nanri T, Matsuno N, Kawakita T, Mitsuya H, Asou N.
Haematologica 94(3):433-5. Epub 2009 Jan 30. No abstract available. 2009
18AMKLDS, JAK2
Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.
Gaikwad A, Rye CL, Devidas M, Heerema NA, Carroll AJ, Izraeli S, Plon SE, Basso G, Pession A, Rabin KR.
Br J Haematol 144(6):930-2. Epub 2008 Dec 20. 2009
19AMKLDS, JAK2
Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.
Kearney L, Gonzalez De Castro D, Yeung J, Procter J, Horsley SW, Eguchi-Ishimae M, Bateman CM, Anderson K, Chaplin T, Young BD, Harrison CJ, Kempski H, So CW, Ford AM, Greaves M.
Blood 113(3):646-8. Epub 2008 Oct 16. 2009
20JAK2, MPD
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.
Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Collins A, Reiter A, Grand F, Cross NC.
Nat Genet 41(4):446-9. Epub 2009 Mar 15. 2009
21JAK2, MPD
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL.
Nat Genet 41(4):455-9. Epub 2009 Mar 15. 2009
22JAK2, MPD
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.
Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabinger I, Gisslinger H, Kralovics R.
Nat Genet 41(4):450-4. Epub 2009 Mar 15. 2009
23FABP4, JAK2
Interaction of adipocyte fatty acid-binding protein (AFABP) and JAK2: AFABP/aP2 as a regulator of JAK2 signaling.
Thompson BR, Mazurkiewicz-Muñoz AM, Suttles J, Carter-Su C, Bernlohr DA.
J Biol Chem 284(20):13473-80. Epub 2009 Mar 23. 2009
24JAK1, JAK2, JAK3
JAK mutations in high-risk childhood acute lymphoblastic leukemia.
Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, Tasian SK, Loh ML, Su X, Liu W, Devidas M, Atlas SR, Chen IM, Clifford RJ, Gerhard DS, Carroll WL, Reaman GH, Smith M, Downing JR, Hunger SP, Willman CL.
Proc Natl Acad Sci U S A 106(23):9414-8. Epub 2009 May 22. 2009
25BCR, JAK2
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia.
Cirmena G, Aliano S, Fugazza G, Bruzzone R, Garuti A, Bocciardi R, Bacigalupo A, Ravazzolo R, Ballestrero A, Sessarego M.
Cancer Genet Cytogenet 183(2):105-8. 2008
26JAK2, STAT2, STAT3
JAK2/STAT2/STAT3 are required for myogenic differentiation.
Wang K, Wang C, Xiao F, Wang H, Wu Z.
J Biol Chem 283(49):34029-36. Epub 2008 Oct 2. 2008
27JAK2, MPD, MPL, PRV
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
Kilpivaara O, Levine RL.
Leukemia 22(10):1813-7. Epub 2008 Aug 28. Review. 2008
28JAK2, MPD, PML, PRV
Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Tefferi A.
Am J Hematol 83(6):491-7. Review. 2008
29JAK2, MPD, MPL
Myeloproliferative disorders.
Levine RL, Gilliland DG.
Blood 112(6):2190-8. Review. 2008
30JAK2, SSBP2
Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia.
Poitras JL, Dal Cin P, Aster JC, Deangelo DJ, Morton CC.
Genes Chromosomes Cancer 47(10):884-9. 2008
31JAK2, JAK3, MPD, MPL
JAK and MPL mutations in myeloid malignancies.
Tefferi A.
Leuk Lymphoma 49(3):388-97. Review. 2008
32JAK2
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.
Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, Shochat C, Cazzaniga G, Biondi A, Basso G, Cario G, Schrappe M, Stanulla M, Strehl S, Haas OA, Mann G, Binder V, Borkhardt A, Kempski H, Trka J, Bielorei B, Avigad S, Stark B, Smith O, Dastugue N, Bourquin JP, Tal NB, Green AR, Izraeli S.
Lancet 372(9648):1484-92. Epub 2008 Sep 19. 2008
33JAK2
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.
Plo I, Nakatake M, Malivert L, de Villartay JP, Giraudier S, Villeval JL, Wiesmuller L, Vainchenker W.
Blood 112(4):1402-12. Epub 2008 May 30.PMID: 18515659 2008
34JAK2, MPD, PRV
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR.
N Engl J Med 356(5):459-68. 2007
35JAK2, MPD
Jak2: normal function and role in hematopoietic disorders.
Ihle JN, Gilliland DG.
Curr Opin Genet Dev 17(1):8-14. Epub 2007 Jan 8. 2007
36JAK2, MPD
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.
Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, Jones C, Zehnder JL, Lilleberg SL, Weissman IL.
Proc Natl Acad Sci U S A 103(16):6224-9. Epub 2006 Apr 7. 2006
37PRV, JAK2
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, Yallop D, Arya R, Pagliuca A, GŠken J, Wendon J, Heaton ND, Mufti GJ.
Gastroenterology 130(7):2031-8. 2006
38JAK2, RPN1
Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene.
Mark HF, Sotomayor EA, Nelson M, Chaves F, Sanger WG, Kaleem Z, Caughron SK.
Exp Mol Pathol 81(3):217-23. Epub 2006 Sep 7. 2006
39JAK2, MPD
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W.
Nature 434(7037):1144-8. 2005
40JAK2, MPD
A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.
N Engl J Med 352(17):1779-90. 2005
41BCR, JAK2
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
Griesinger F, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A, Wormann B, Haase D, Bohlander SK.
Genes Chromosomes Cancer 44(3):329-33. 2005
42JAK1, JAK2
Simultaneous activation of JAK1 and JAK2 confers IL-3 independent growth on Ba/F3 pro-B cells.
Huang HM, Lin YL, Chen CH, Chang TW.
J Cell Biochem 96(2):361-75. 2005
43CXCR4, JAK2, STAT3
Identification of the cytoplasmic domains of CXCR4 involved in Jak2 and STAT3 phosphorylation.
Ahr B, Denizot M, Robert-Hebmann V, Brelot A, Biard-Piechaczyk M.
J Biol Chem 280(8):6692-700. Epub 2004 Dec 22. 2005
44JAK2, PCM1
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, Laurent G, Dastugue N, Brousset P.
Oncogene 24(48):7248-52. 2005
45CALM1, EPOR, JAK2
Calmodulin physically interacts with the erythropoietin receptor and enhances Jak2-mediated signaling.
Kakihana K, Yamamoto M, Iiyama M, Miura O.
Biochem Biophys Res Commun 335(2):424-31. 2005
46HES5, JAK2
Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT signalling.
Kamakura S, Oishi K, Yoshimatsu T, Nakafuku M, Masuyama N, Gotoh Y.
Nat Cell Biol. 6(6):547-54. 2004
47JAK2
Jak2 is involved in c-Myc induction by Bcr-Abl.
Xie S, Lin H, Sun T, Arlinghaus RB.
Oncogene. 21(47):7137-46. 2002
48JAK2, STAT3
ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner.
Ren Z, Schaefer TS.
J Biol Chem. 277(41):38486-93. 2002
49JAK2
Requirement of Ca(2+) and PKCdelta for Janus kinase 2 activation by angiotensin II: involvement of PYK2.
Frank GD, Saito S, Motley ED, Sasaki T, Ohba M, Kuroki T, Inagami T, Eguchi S.
Mol Endocrinol. 16(2):367-77. 2002
50JAK2
Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.
Ungureanu D, Saharinen P, Junttila I, Hilton DJ, Silvennoinen O.
Mol Cell Biol. 22(10):3316-26. 2002
51DNAJA3, JAK2
hTid-1, a human DnaJ protein, modulates the interferon signaling pathway.
Sarkar S, Pollack BP, Lin KT, Kotenko SV, Cook JR, Lewis A, Pestka S.
J Biol Chem 276(52):49034-42. 2001
52BRCA1, JAK2, STAT3
Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells.
Gao B, Shen X, Kunos G, Meng Q, Goldberg ID, Rosen EM, Fan S.
FEBS Lett. 488(3):179-84. 2001
53JAK2
TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B.
Myers MP, Andersen JN, Cheng A, Tremblay ML, Horvath CM, Parisien JP, Salmeen A, Barford D, Tonks NK.
J Biol Chem. 276(51):47771-4. 2001
54JAK2
The protein tyrosine phosphatase-PEST is implicated in the negative regulation of epidermal growth factor on PRL signaling in mammary epithelial cells.
Horsch K, Schaller MD, Hynes NE.
Mol Endocrinol. 15(12):2182-96 2001
55JAK2, STAM2
STAM2, a new member of the STAM family, binding to the Janus kinases.
Endo K, Takeshita T, Kasai H, Sasaki Y, Tanaka N, Asao H, Kikuchi K, Yamada M, Chenb M, O'Shea JJ, Sugamura K.
FEBS Lett 477(1-2):55-61. 2000
56GHTF, JAK2, STAT3
Involvement of JAK/STAT (Janus kinase/signal transducer and activator of transcription) in the thyrotropin signaling pathway.
Park ES, Kim H, Suh JM, Park SJ, You SH, Chung HK, Lee KW, Kwon OY, Cho BY, Kim YK, Ro HK, Chung J, Shong M.
Mol Endocrinol 14(5):662-70. 2000
57CTLA4, JAK2
Janus kinase 2 is associated with a box 1-like motif and phosphorylates a critical tyrosine residue in the cytoplasmic region of cytotoxic T lymphocyte associated molecule-4.
Chikuma S, Murakami M, Tanaka K, Uede T.
J Cell Biochem. 78(2):241-50. 2000
58JAK2
Molecular cloning and characterization of CRLM-2, a novel type I cytokine receptor preferentially expressed in hematopoietic cells.
Hiroyama T, Iwama A, Morita Y, Nakamura Y, Shibuya A, Nakauchi H.
Biochem Biophys Res Commun. 272(1):224-9. 2000
59JAK2
SH2-Containing protein tyrosine phosphatase-1 (SHP-1) association with Jak2 in UT-7/Epo cells.
Wu DW, Stark KC, Dunnington D, Dillon SB, Yi T, Jones C, Pelus LM.
Blood Cells Mol Dis. 26(1):15-24. 2000
60JAK2
Negative regulation of growth hormone receptor/JAK2 signaling by signal regulatory protein alpha.
Stofega MR, Argetsinger LS, Wang H, Ullrich A, Carter-Su C.
J Biol Chem. 275(36):28222-9. 2000
61JAK2
Genomic organization of human JAK2 and mutation analysis of its JH2-domain in leukemia.
Cools J, et al.
Cytogenet Cell Genet 85(3-4):260-266. 1999
62JAK2, PRMT5
The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity.
Pollack BP, Kotenko SV, He W, Izotova LS, Barnoski BL, Pestka S.
J Biol Chem 274(44):31531-42. 1999
63JAK2
The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway.
Vila-Coro AJ, Rodríguez-Frade JM, Martín De Ana A, Moreno-Ortíz MC, Martínez-A C, Mellado M.
FASEB J. 13(13):1699-710. 1999
64JAK2
The growth hormone receptor associates with Jak1, Jak2 and Tyk2 in human liver.
Hellgren G, Jansson JO, Carlsson LM, Carlsson B.
Growth Horm IGF Res. 9(3):212-8. 1999
65JAK2
Physical interaction between interleukin-12 receptor beta 2 subunit and Jak2 tyrosine kinase: Jak2 associates with cytoplasmic membrane-proximal region of interleukin-12 receptor beta 2 via amino-terminus.
Yamamoto K, Shibata F, Miura O, Kamiyama R, Hirosawa S, Miyasaka N.
Biochem Biophys Res Commun. 257(2):400-4. 1999
66JAK2
Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain.
Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA, Yoshimura A.
Genes Cells. 4(6):339-51 1999
67JAK2
Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis.
Neubauer H, et al.
Cell 93 : 397-409. 1998
68JAK2
Jak2 is essential for signaling through a variety of cytokine receptors.
Parganas E, et al.
Cell 93 : 385-395. 1998
69JAK2
Cloning and characterization of human Jak-2 kinase : high mRNA expression in immune cells and muscle tissue.
Saltzman A, et al.
Biochem Biophys Res Commun 246 : 627-633. 1998
70JAK2
Growth hormone-dependent tyrosine phosphorylation of a GH receptor-associated high molecular WEIGHT protein immunologically related to JAK2.
iang J, et al.
Biochem Biophys Res Commun 253(3):774-9. 1998
71JAK2
Cloning and characterization of human Jak-2 kinase: high mRNA expression in immune cells and muscle tissue.
Saltzman A, Stone M, Franks C, Searfoss G, Munro R, Jaye M, Ivashchenko Y.
Biochem Biophys Res Commun 246(3):627-33. 1998
72CCR2, JAK2, CCL2
The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor.
Mellado M, Rodriguez-Frade JM, Aragay A, del Real G, Martin AM, Vila-Coro AJ, Serrano A, Mayor F Jr, Martinez-A C.
J Immunol 161(2):805-13. 1998
73JAK2, PTK2
Growth hormone stimulates the tyrosine phosphorylation and association of p125 focal adhesion kinase (FAK) with JAK2. Fak is not required for stat-mediated transcription.
Zhu T, Goh EL, Lobie PE.
J Biol Chem. 273(17):10682-9. 1998
74JAK2
Grb10 identified as a potential regulator of growth hormone (GH) signaling by cloning of GH receptor target proteins.
Moutoussamy S, Renaudie F, Lago F, Kelly PA, Finidori J.
J Biol Chem. 273(26):15906-12. 1998
75JAK2
Interaction of Janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulin-like growth factor-1 receptor.
Gual P, Baron V, Lequoy V, Van Obberghen E.
Endocrinology. 139(3):884-93. 1998
76JAK2
JAK2 and JAK1 constitutively associate with an interleukin-5 (IL-5) receptor alpha and betac subunit, respectively, and are activated upon IL-5 stimulation.
Ogata N, Kouro T, Yamada A, Koike M, Hanai N, Ishikawa T, Takatsu K.
Blood. 91(7):2264-71. 1998
77JAK2
Midkine induces tumor cell proliferation and binds to a high affinity signaling receptor associated with JAK tyrosine kinases.
Ratovitski EA, Kotzbauer PT, Milbrandt J, Lowenstein CJ, Burrow CR.
J Biol Chem. 273(6):3654-60. 1998
78JAK2
Induction of Jak/STAT signaling by activation of the type 1 TNF receptor.
Guo D, Dunbar JD, Yang CH, Pfeffer LM, Donner DB.
J Immunol. 160(6):2742-50. 1998
79JAK2
Tec and Jak2 kinases cooperate to mediate cytokine-driven activation of c-fos transcription.
Yamashita Y, Watanabe S, Miyazato A, Ohya K, Ikeda U, Shimada K, Komatsu N, Hatake K, Miura Y, Ozawa K, Mano H.
Blood. 91(5):1496-507. 1998
80ETV6, JAK2
A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.
Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA.
Science 278(5341):1309-12. 1997
81JAK2
Differential associations between the cytoplasmic regions of the interleukin-12 receptor subunits beta1 and beta2 and JAK kinases.
Zou J, Presky DH, Wu CY, Gubler U.
J Biol Chem. 272(9):6073-7. 1997
82JAK2
Identification of SH2-Bbeta as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling.
Rui L, Mathews LS, Hotta K, Gustafson TA, Carter-Su C.
Mol Cell Biol. 17(11):6633-44. 1997
83JAK2
Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase.
Giordano V, De Falco G, Chiari R, Quinto I, Pelicci PG, Bartholomew L, Delmastro P, Gadina M, Scala G.
J Immunol. 158(9):4097-103. 1997
84JAK2
An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT.
Fujitani Y, Hibi M, Fukada T, Takahashi-Tezuka M, Yoshida H, Yamaguchi T, Sugiyama K, Yamanaka Y, Nakajima K, Hirano T.
Oncogene. 14(7):751-61 1997
85JAK2
Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase.
Ram PA, Waxman DJ.
J Biol Chem. 272(28):17694-702. 1997
86JAK2
IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling.
Murata T, Noguchi PD, Puri RK.
J Immunol. 156(8):2972-8. 1996
87JAK2
JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor.
Weiler SR, Mou S, DeBerry CS, Keller JR, Ruscetti FW, Ferris DK, Longo DL, Linnekin D.
Blood. 87(9):3688-93. 1996
88JAK2
Complex formation of JAK2 with PP2A, P13K, and Yes in response to the hematopoietic cytokine interleukin-11.
Fuhrer DK, Yang YC.
Biochem Biophys Res Commun. 224(2):289-96. 1996
89JAK2
Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor.
Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P, Bernstein KE.
Nature. 375(6528):247-50. 1995
90JAK2
The amino-terminal portion of the JAK2 protein kinase is necessary for binding and phosphorylation of the granulocyte-macrophage colony-stimulating factor receptor beta c chain.
Zhao Y, Wagner F, Frank SJ, Kraft AS.
J Biol Chem. 270(23):13814-8. 1995
91JAK2
Syp associates with gp130 and Janus kinase 2 in response to interleukin-11 in 3T3-L1 mouse preadipocytes.
Fuhrer DK, Feng GS, Yang YC.
J Biol Chem. 270(42):24826-30. 1995
92JAK2
Interferon-gamma induces tyrosine phosphorylation of interferon-gamma receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor.
Igarashi K, Garotta G, Ozmen L, Ziemiecki A, Wilks AF, Harpur AG, Larner AC, Finbloom DS.
J Biol Chem. 269(20):14333-6. 1994
93JAK1, JAK2
Two members of the JAK family of protein tyrosine kinases map to chromosomes 1p31.3 and 9p24.
Pritchard MA, et al.
Mamm Genome 3 : 36-38. 1992
94JAK1, JAK2
Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase.
Wilks AF, et al.
Mol Cell Biol 11 : 2057-2065. 1991